Oppenheimer Maintains Outperform on Dollar General, Raises Price Target to $270

Oppenheimer analyst Rupesh Parikh maintains Dollar General (NYSE:DG) with a Outperform and raises the price target from $225 to $270.

byBenzinga Newsdesk

July 15, 2021

1 minute read

Oppenheimer analyst Rupesh Parikh maintains Dollar General (NYSE:DG) with a Outperform and raises the price target from $225 to $270.

SciSparc Signs Non-Binding LOI To Sell A 50% Interest In Its Subsidiary That Owns Wellution

By Vuk Zdinjak

Today, 5:26 AM

SciSparc Ltd. (NASDAQ: SPRC) has entered into a non-binding letter of intent for the sale of a 50% interest in its wholly owned subsidiary, SciSparc Nutraceuticals Inc., which owns Wellution, to Jeffs' Brands Ltd. (NASD

AMZN

Cannabis Dispensary Roundup: Ascend Wellness, Berner’s Cookies, Verano, Khiron, & EmporaPharma

By Nina Zdinjak

Today, 5:26 AM

Ascend Wellness Begins Operations At Third New Jersey Dispensary

AAWH

Jefferies Downgrades F N B to Hold, Lowers Price Target to $12

By Benzinga Newsdesk

Today, 5:26 AM

Jefferies analyst Casey Haire downgrades F N B (NYSE:FNB) from Buy to Hold and lowers the price target from $14 to $12.

FNB

Why This Analyst Is Recommending Owning Apple Shares Ahead Of March Quarter Results

By Shanthi Rexaline

Today, 5:26 AM

Reports of production disruptions at major suppliers have left Apple, Inc. (NASDAQ: AAPL) may have some investors worried but an analyst at KeyBanc Capital Markets is confident of Cupertino turning in another strong quarter when it reports later this month.

AAPL

Oppenheimer Maintains Outperform on Dollar General, Raises Price Target to $270

Related Posts

SciSparc Signs Non-Binding LOI To Sell A 50% Interest In Its Subsidiary That Owns Wellution

Cannabis Dispensary Roundup: Ascend Wellness, Berner’s Cookies, Verano, Khiron, & EmporaPharma

Jefferies Downgrades F N B to Hold, Lowers Price Target to $12

Why This Analyst Is Recommending Owning Apple Shares Ahead Of March Quarter Results